Multifaceted actions of 8-amino-adenosine kill BCR–ABL positive cells

References

• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. A minute chromosome 21 in human chronic granulocytic leukemia. Science 1964;132:1497.
   Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
   PubMed Web of Science ®Google Scholar
• Laurent E, Talpaz M, Kantarjian H, . The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001;61:2343–2355.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, Naekyung Kim C, Liu L, . Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700–1705.
   PubMed Web of Science ®Google Scholar
• Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96:2269–2276.
   PubMed Web of Science ®Google Scholar
• Reuther JY, Reuther GW, Cortez D, . A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998;12:968–981.
   PubMed Web of Science ®Google Scholar
• Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003;40:4–10.
   PubMed Web of Science ®Google Scholar
• Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002;16:1402–1411.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L, . Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380–394.
   PubMed Web of Science ®Google Scholar
• McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987;84:6558–6562.
   PubMed Web of Science ®Google Scholar
• Collins SJ, Groudine MT. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood 1987;69:893–898.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Timson L, Kawasaki ES, . Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:563–567.
   PubMed Web of Science ®Google Scholar
• Dilloo D, Hanenberg H, Lion T, . IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein. Leukemia 1995;9:419–424.
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Blick M, Evinger-Hodges MJ, . Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer 1988;62:1171–1178.
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, . Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236–4243.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Cambier N, Chopra R, Strasser A, . BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998;16:335–348.
   PubMed Web of Science ®Google Scholar
• Gaiger A, Henn T, Horth E, . Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995;86:2371–2378.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Tassi E, Varella-Garcia M, . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Hantschel O, Kaupe I, . BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 2010;116:3278–3285.
   PubMed Web of Science ®Google Scholar
• La Rosee P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol 2010;47:335–343.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, . BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–698.
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr- Abl positive acute leukemias: beyond STI571. Oncogene 2002;21: 8584–8590.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol 2009;147:297–307.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Shanmugam M, Ayres ML, . 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 2010;116:5622–5630.
   PubMed Web of Science ®Google Scholar
• Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther 2010;9:236–245.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Ayres M, Halgren RG, . 8-Chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 2001;61:5474–5479.
   PubMed Web of Science ®Google Scholar
• Stellrecht CM, Rodriguez CO Jr, Ayres M, . RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 2003;63:7968–7974.
   PubMed Web of Science ®Google Scholar
• Beran M, Pisa P, O’Brien S, . Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993;53:3603–3610.
   PubMed Web of Science ®Google Scholar
• Ricci C, Scappini B, Divoky V, . Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002;62:5995–5998.
   PubMed Web of Science ®Google Scholar
• Rodriguez CO Jr, Plunkett W, Paff MT, . High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 2000;745:421–430.
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Bearss D, . Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150–4157.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31–36.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Luger SM, O’Brien SG, Ratajczak J, . Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002;99:1150–1158.
   PubMed Web of Science ®Google Scholar
• Skorski T, Nieborowska-Skorska M, Wlodarski P, . Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997;89:124–133.
   PubMed Web of Science ®Google Scholar
• Spiller DG, Giles RV, Grzybowski J, . Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood 1998;91:4738–4746.
   PubMed Web of Science ®Google Scholar
• Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood 2000;95:731–737.
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959–10966.
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Mahon FX, Zafirides G, . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16:2349–2357.
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Bali P, O’Bryan E, . Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003;63:7950–7958.
   PubMed Web of Science ®Google Scholar
• Dhut S, Chaplin T, Young BD. BCR-ABL and BCR proteins: biochemical characterization and localization. Leukemia 1990;4:745–750.
   PubMed Web of Science ®Google Scholar
• Ayoubi M, Kantarjian HM, Wierda W, . A phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. Blood 2009;114(Suppl. 1): Abstract 2193.
   Google Scholar
• Krett NL, Davies KM, Ayres M, . 8-Amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther 2004;3:1411–1420.
   PubMed Web of Science ®Google Scholar
• Ghias K, Ma C, Gandhi V, . 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther 2005;4:569–577.
   PubMed Web of Science ®Google Scholar
• Chen LS, Sheppard TL. Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs. J Biol Chem 2004;279:40405–40411.
   PubMed Web of Science ®Google Scholar
• Chen LS, Du-Cuny L, Vethantham V, . Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol 2010;79:669–677.
   PubMed Web of Science ®Google Scholar
• Chen LS, Nowak BJ, Ayres ML, . Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol 2009;78:583–591.
   PubMed Web of Science ®Google Scholar
• Fainstein E, Einat M, Gokkel E, . Nucleotide sequence analysis of human abl and bcr-abl cDNAs. Oncogene 1989;4:1477–1481.
   PubMed Web of Science ®Google Scholar
• Marega M, Piazza RG, Pirola A, . BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia 2010;24:1445–1449.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Ceriani MC, Capaccioli S, . Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003;195:356–372.
   PubMed Web of Science ®Google Scholar
• Lam LT, Pickeral OK, Peng AC, . Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
   PubMed Web of Science ®Google Scholar
• Drevs J, Medinger M, Schmidt-Gersbach C, . Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets 2003;4:113–121.
   PubMed Web of Science ®Google Scholar
• Shanmugam M, McBrayer SK, Qian J, . Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem 2009;284:26816–26830.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Shang L, Wang X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy 2011;7: 924–926.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, . Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022–4028.
   PubMed Web of Science ®Google Scholar